Literature DB >> 23261076

Dopamine agonist-induced impulse control disorders in a patient with prolactinoma.

Santiago Almanzar1, Maria I Zapata-Vega, Juan A Raya.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261076     DOI: 10.1016/j.psym.2012.10.002

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


× No keyword cloud information.
  5 in total

Review 1.  Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy.

Authors:  Anahid Hamidianjahromi; Nicholas A Tritos
Journal:  Rev Endocr Metab Disord       Date:  2022-09-20       Impact factor: 9.306

2.  Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study.

Authors:  Irina Bancos; Michael R Nannenga; J Michael Bostwick; Michael H Silber; Dana Erickson; Todd B Nippoldt
Journal:  Clin Endocrinol (Oxf)       Date:  2013-12-16       Impact factor: 3.478

3.  Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study.

Authors:  M Zibetti; S Grottoli; G Beccuti; F Guaraldi; G Natta; V Cambria; N Prencipe; A Cicolin; E Montanaro; L Lopiano; E Ghigo
Journal:  J Endocrinol Invest       Date:  2020-12-12       Impact factor: 4.256

Review 4.  Dopamine Agonists and Impulse Control Disorders: A Complex Association.

Authors:  Marie Grall-Bronnec; Caroline Victorri-Vigneau; Yann Donnio; Juliette Leboucher; Morgane Rousselet; Elsa Thiabaud; Nicolas Zreika; Pascal Derkinderen; Gaëlle Challet-Bouju
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

Review 5.  Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Authors:  Anastasia P Athanasoulia-Kaspar; Kathrin H Popp; Gunter Karl Stalla
Journal:  Endocr Connect       Date:  2018-01-29       Impact factor: 3.335

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.